This database contains 145 studies, archived under the term: "patients"
Click here to filter this large number of results.
Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study
Mild cognitive impairment (MCI) in Parkinson’s disease (PD) may be associated with subtle functional impairment and worse quality of life. The objective of this study was to determine the efficacy and tolerability of rivastigmine for PD-MCI. Patients with PD-MCI (n = 28) were enrolled in a 24-week, randomized, double-blind, placebo-controlled, crossover, single-site study of the rivastigmine transdermal […]
Treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in Alzheimer’s disease: A longitudinal functional MRI study
Thiyagesh, Subha N.,
Farrow, Tom F. D.,
Parks, Randolph W.,
Accosta-Mesa, Hector,
Hunter, Michael D.,
Young, Claire,
Wilkinson, lain D.,
Woodruff, Peter W. R.
Background/Aims: Visuospatial impairments are known to occur in Alzheimer’s disease (AD). We hypothesised that functional magnetic resonance imaging (fMRI) response in task-related brain regions would be impaired in patients with AD during the task and that treatment with acetyl cholinesterase inhibitors would enhance activations in brain regions concerned with this visual perceptual processing. Method: Ten […]
Evaluating rivastigmine in mild-to-moderate Parkinson’s disease dementia using ADAS-cog items
Schmitt, Frederick A.,
Aarsland, Dag,
Brønnick, Kolbjørn S.,
Meng, Xiangyi,
Tekin, Sibel,
Olin, Jason T.
Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale—cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for […]
How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist
Sakakibara, Ryuji,
Ogata, Takeshi,
Uchiyama, Tomoyuki,
Kishi, Masahiko,
Ogawa, Emina,
Isaka, Shigeo,
Yuasa, Joji,
Yamamoto, Tatsuya,
Ito, Takashi,
Yamanishi, Tomonori,
Awa, Yusuke,
Yamaguchi, Chiharu,
Takahashi, Osamu
Although urinary incontinence inevitably occurs in advanced stages of dementia of any etiology, urinary urgency or frequency, also called an overactive bladder (OAB), occurs more commonly in dementia with Lewy bodies (DLB) and vascular dementia than it does in Alzheimer’s disease (AD). Acetylcholinesterase (AChE) inhibitors for dementia and anticholinergics for OAB have been widely used, […]
No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer’s disease
Objective: Work in experimental animals suggests that an interaction with dopaminergic networks might explain some of the therapeutic effects of the cholinesterase inhibitor class of drugs. This study aimed to test whether acute (single 5 mg) or 4–8 weeks (5–10 mg) of treatment with oral donepezil would elicit measurable striatal dopamine (DA) release in patients […]
A serum protein-based algorithm for the detection of Alzheimer disease
O'Bryant, Sid E.,
Xiao, Guanghua,
Barber, Robert,
Reisch, Joan,
Doody, Rachelle,
Fairchild, Thomas,
Adams, Perrie,
Waring, Steven,
Diaz-Arrastia, Ramon
Objective: To develop an algorithm that separates patients with Alzheimer disease (AD) from controls. Design: Longitudinal case-control study. Setting: The Texas Alzheimer’s Research Consortium project. Patients: We analyzed serum protein-based multiplex biomarker data from 197 patients diagnosed with AD and 203 controls. Main Outcome Measure: The total sample was randomized equally into training and test […]